Peyronel Francesco, Parenti Elisabetta, Fenaroli Paride, Benigno Giuseppe Daniele, Rossi Giovanni Maria, Maggiore Umberto, Fiaccadori Enrico
Unità Operativa di Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Parma, Emilia-Romagna, Italy
Scuola di Specializzazione in Nefrologia, Università degli Studi di Parma Dipartimento di Medicina e Chirurgia, Parma, Emilia-Romagna, Italy.
BMJ Open. 2020 Jul 8;10(7):e036893. doi: 10.1136/bmjopen-2020-036893.
In patients on maintenance haemodialysis (HD), intradialytic hypotension (IDH) is a clinical problem that nephrologists and dialysis nurses face daily in their clinical routine. Despite the technological advances in the field of HD, the incidence of hypotensive events occurring during a standard dialytic treatment is still very high. Frequently recurring hypotensive episodes during HD sessions expose patients not only to severe immediate complications but also to a higher mortality risk in the medium term. Various strategies aimed at preventing IDH are currently available, but there is lack of conclusive data on more integrated approaches combining different interventions.
This is a prospective, randomised, open-label, crossover trial (each subject will be used as his/her own control) that will be performed in two distinct phases, each of which is divided into several subphases. In the first phase, 27 HD sessions for each patient will be used, and will be aimed at the validation of a new ultrafiltration (UF) profile, designed with an ascending/descending shape, and a standard dialysate sodium concentration. In the second phase, 33 HD sessions for each patient will be used and will be aimed at evaluating the combination of different UF and sodium profiling strategies through individualised dialysate sodium concentration.
The trial protocol has been reviewed and approved by the local Institutional Ethics Committee (Comitato Etico AVEN, prot. 43391 22.10.19). The results of the trial will be presented at local and international conferences and submitted for publication to a peer-reviewed journal.
ClinicalTrials.gov Registry (NCT03949088).
在维持性血液透析(HD)患者中,透析中低血压(IDH)是肾病学家和透析护士在日常临床工作中每天都会面临的临床问题。尽管血液透析领域有技术进步,但在标准透析治疗期间发生低血压事件的发生率仍然很高。血液透析过程中频繁复发的低血压发作不仅使患者面临严重的即时并发症,而且在中期还面临更高的死亡风险。目前有各种旨在预防IDH的策略,但关于结合不同干预措施的更综合方法缺乏确凿数据。
这是一项前瞻性、随机、开放标签、交叉试验(每个受试者将作为自己的对照),将分两个不同阶段进行,每个阶段又分为几个子阶段。在第一阶段,将为每位患者进行27次血液透析治疗,目的是验证一种新的超滤(UF)模式,该模式设计为上升/下降形状,以及标准透析液钠浓度。在第二阶段,将为每位患者进行33次血液透析治疗,目的是通过个体化透析液钠浓度评估不同超滤和钠模式策略的组合。
试验方案已由当地机构伦理委员会(Comitato Etico AVEN,编号43391 22.10.19)审查并批准。试验结果将在当地和国际会议上公布,并提交给同行评审期刊发表。
ClinicalTrials.gov注册库(NCT03949088)。